New combo aims to stall aggressive lung cancer
NCT ID NCT07376499
First seen Jan 29, 2026 · Last updated Jun 20, 2026 · Updated 21 times
Summary
This phase 2 trial tests a four-drug maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes liposome irinotecan, platinum chemotherapy, an immune checkpoint inhibitor (toripalimab), and an anti-angiogenic drug (anlotinib). The goal is to see if this regimen can delay cancer progression and improve survival. The study plans to enroll 31 participants and is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liposome irinotecan, platinum (carboplatin or cisplatin), anlotinib, and toripalimab
What this could lead to
If successful, this combination could offer a new maintenance option to keep extensive small cell lung cancer from progressing longer after initial treatment.
What could go wrong
This is a small, early-phase (phase 2) trial with only 31 people, so results may not apply broadly. The drug combo also carries risks like severe side effects from chemotherapy and immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.